<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">TCM</journal-id><journal-title-group><journal-title>Traditional Chinese Medicine</journal-title></journal-title-group><issn pub-type="epub">2166-6067</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/TCM.2020.94052</article-id><article-id pub-id-type="publisher-id">TCM-36486</article-id><article-categories><subj-group subj-group-type="heading"><subject>TCM20200400000_47187159.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  肠道菌群在自身免疫性肝病中的治疗进展
  Progress of Intestinal Flora in the Treatment of Autoimmune Liver Disease
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>石</surname><given-names>莉杰</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>雪微</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>艳英</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>沙</surname><given-names>敏</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>诸</surname><given-names>慧怡</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>何</surname><given-names>进</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>黄</surname><given-names>天生</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>上海中医药大学，上海</addr-line></aff><aff id="aff3"><addr-line>上海市光华中西医结合医院，上海</addr-line></aff><aff id="aff2"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>06</month><year>2020</year></pub-date><volume>09</volume><issue>04</issue><fpage>348</fpage><lpage>353</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   已经有研究证明肠道菌群失调可以导致人体多器官多系统病变，肠道微生物以其组成上的多样性、结构上的复杂性来维持稳态，调节人体生理机能和病理状态。免疫系统是人体一个重要的防御系统，影响因素众多，其中肠道菌群在维持人体免疫系统稳态的过程中发挥重要作用。因此建立和维持肠道菌群与免疫系统之间的和谐关系是保障机体健康的关键。近年来不少研究提出肠道菌群在自身免疫性肝病的发生发展中起到了重要作用，激起了广大学者的研究热情，因此人们开始探索通过调节肠道菌群来治疗自身免疫性肝病并取得了确切的疗效。本文就通过调节肠道菌群治疗自身免疫性肝病的进展做一综述。 Studies have shown that disorders of intestinal flora can lead to diseases of multiple organs and systems in the human body. Intestinal microorganisms maintain homeostasis and regulate physi-ological function and pathological state of human body with their diversity in composition and complexity in structure. Immune system is an important defense system of human body, and there are many influencing factors, among which intestinal flora plays an important role in maintaining the homeostasis of human immune system. Therefore, establishing and maintaining a harmonious relationship between the intestinal flora and the immune system is the key to ensure the health of the body. In recent years, many studies have suggested that intestinal flora plays an important role in the development of autoimmune liver disease, which has aroused the enthusiasm of many scholars, therefore, people began to explore the treatment of autoimmune liver disease by regu-lating intestinal flora and achieved a definite effect. This article reviews the progress of treating autoimmune liver disease by regulating intestinal flora. 
 
</p></abstract><kwd-group><kwd>自身免疫性肝病，肠道菌群，祖国医学，现代医学, Autoimmune Liver Disease</kwd><kwd> Intestinal Flora</kwd><kwd> Traditional Chinese Medicine</kwd><kwd> Modern Medicine</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>肠道菌群在自身免疫性肝病中的治疗进展<sup> </sup></title><p>石莉杰<sup>1*</sup>，李雪微<sup>2</sup>，李艳英<sup>2</sup>，沙敏<sup>1</sup>，诸慧怡<sup>1</sup>，何进<sup>1</sup>，黄天生<sup>2#</sup></p><p><sup>1</sup>上海中医药大学，上海</p><p><sup>2</sup>上海市光华中西医结合医院，上海</p><disp-formula id="hanspub.36486-formula14"><graphic xlink:href="//html.hanspub.org/file/9-2270554x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2020年6月19日；录用日期：2020年7月6日；发布日期：2020年7月13日</p><disp-formula id="hanspub.36486-formula15"><graphic xlink:href="//html.hanspub.org/file/9-2270554x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>已经有研究证明肠道菌群失调可以导致人体多器官多系统病变，肠道微生物以其组成上的多样性、结构上的复杂性来维持稳态，调节人体生理机能和病理状态。免疫系统是人体一个重要的防御系统，影响因素众多，其中肠道菌群在维持人体免疫系统稳态的过程中发挥重要作用。因此建立和维持肠道菌群与免疫系统之间的和谐关系是保障机体健康的关键。近年来不少研究提出肠道菌群在自身免疫性肝病的发生发展中起到了重要作用，激起了广大学者的研究热情，因此人们开始探索通过调节肠道菌群来治疗自身免疫性肝病并取得了确切的疗效。本文就通过调节肠道菌群治疗自身免疫性肝病的进展做一综述。</p><p>关键词 :自身免疫性肝病，肠道菌群，祖国医学，现代医学</p><disp-formula id="hanspub.36486-formula16"><graphic xlink:href="//html.hanspub.org/file/9-2270554x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/9-2270554x8_hanspub.png" /> <img src="//html.hanspub.org/file/9-2270554x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 肠道菌群</title><p>胃肠道是一个复杂而庞大的微生物系统，人体肠道微生物的数量约为10<sup>14</sup>个，肠道细菌基因的数量大约是人类基因的100倍 [<xref ref-type="bibr" rid="hanspub.36486-ref1">1</xref>]。人体肠道菌群包括多种益生菌和致病菌，这些菌群在体内的平衡是维持人体正常生理功能的保障，肠道微生物群的组成和功能受到遗传、种族、饮食、分娩方式、地理位置和接受药物治疗等多种因素的影响 [<xref ref-type="bibr" rid="hanspub.36486-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.36486-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.36486-ref4">4</xref>]，并与人体的生理病理密切相关。我们的肠道微生物群受到多种因素的干扰就可能造成失调，从而导致免疫、代谢等功能的紊乱而致病 [<xref ref-type="bibr" rid="hanspub.36486-ref5">5</xref>] - [<xref ref-type="bibr" rid="hanspub.36486-ref10">10</xref>]，如胰岛素抵抗、糖尿病和肝脏疾病等。几年前的一项研究 [<xref ref-type="bibr" rid="hanspub.36486-ref11">11</xref>] 证实了无菌小鼠的脾脏发育存在一定的缺陷，而利用菌群干预以后，脾脏的缺陷则逐渐好转，说明肠道菌群参与了免疫系统的发育。1921年HOEFERT首次提出肠道菌群与慢性肝病可能有一定的相关性 [<xref ref-type="bibr" rid="hanspub.36486-ref12">12</xref>]，随后有大量研究也证实了肠道内微环境的破坏和肠道微生物群改变参与了肝病的发生 [<xref ref-type="bibr" rid="hanspub.36486-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.36486-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.36486-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.36486-ref16">16</xref>]。肠道菌群参与包括自身免疫性疾病在内的多种疾病的过程 [<xref ref-type="bibr" rid="hanspub.36486-ref17">17</xref>]。某些特定的肠道细菌具有强烈的致病性，可以通过激活肝细胞的自身免疫系统而攻击自身肝细胞，造成肝细胞损伤以及肝功能受损，进而参与了自身免疫性肝病的疾病发生过程 [<xref ref-type="bibr" rid="hanspub.36486-ref18">18</xref>]。可能是由于肠道炎症改变了肠道的本身的通透性，使肠道菌群或者其代谢产物随血液循环进入到肝脏门静脉系统，定植于肝脏而启动机体免疫应答而造成。</p></sec><sec id="s4"><title>2. 自身免疫性肝病</title><p>祖国医学没有明确的记载自身免疫性肝病的病名，但根据其临床症状、体征、治疗以及预后，结合古代医书所记载的相关内容，如《黄帝内经&#183;素问》篇记载：“肝病者，两胁下痛引少腹”、《素问&#183;五邪篇》云：“邪在肝，则两胁中痛”等，可知本病当属“胁痛”、“黄疸”、“积聚”、“鼓胀”等肝胆系疾病范畴，病位在肝，与胆、脾胃、大肠等相关，其发病是由于饮食失节、劳逸过度、情志失调、禀赋不足等导致机体表现为湿、热、瘀和虚。</p><p>现代医学认为自身免疫性肝病(autoimmune liver disease, AILD)是一组免疫介导的慢性、进展性肝细胞损伤性疾病，主要包括自身免疫性肝炎(autoimmune hepatitis, AIH)、原发性胆汁性胆管炎(primary biliary cholangitis, PBC)、原发性硬化性胆管炎(primary sclerosing cholangitis, PSC)等疾病。其病因和发病机制复杂，目前尚未完全清楚，通常认为与遗传、免疫、炎症、感染以及菌群失调等联系密切，目前尚缺乏特异性诊断标准，治疗上尚无有效的药物能够完全治愈该疾病。研究表明 [<xref ref-type="bibr" rid="hanspub.36486-ref19">19</xref>] 肠源性毒素可以激活肝脏的kuffer细胞，释放炎性因子而损伤免疫系统，且kuffer细胞本身吞噬能力也受到了影响，导致免疫蛋白合成减少，进一步损伤免疫功能。近年来肠道菌群失调在AILD的发生中具有重要作用，并且通过调节肠道菌群来治疗AILD也取得了一定的进展。</p></sec><sec id="s5"><title>3. 药物治疗</title><sec id="s5_1"><title>3.1. AIH</title><p>AIH是一种肝脏的炎症性疾病，血清内可见自身抗体升高 [<xref ref-type="bibr" rid="hanspub.36486-ref20">20</xref>]，目前认为AIH的发病机制主要涉及遗传易感性和分子模拟机制等。HIV的首选治疗方案为泼尼松单药或联合硫唑嘌呤，能够在很大程度上改善患者的症状，减轻肝损伤程度，但是激素治疗副作用较大且不良反应居多 [<xref ref-type="bibr" rid="hanspub.36486-ref22">22</xref>]。因此，人们开始寻求一种绿色安全的治疗方法。</p><p>林睿 [<xref ref-type="bibr" rid="hanspub.36486-ref22">22</xref>] 以细菌16SrDNA荧光定量PCR方法检测AIH患者粪便中的关键细菌的含量，与健康对照组相比较，双歧杆菌、乳酸杆菌等数量减少，双歧杆菌与肠球菌的比值下降，说明AIH患者存在菌群失调现象。菌群失调可以导致肠道粘膜损伤，以致血液中内毒素含量升高，损伤肝脏，诱发AIH的免疫耐受损伤机制。王禾穗源等 [<xref ref-type="bibr" rid="hanspub.36486-ref23">23</xref>] 的动物实验研究，将微生物引入到无菌小鼠体内以后，Th1与Th17含量得到了恢复，又用抗生素杀灭肠道菌群，结果小鼠肝脏内的NKT细胞比例明显下降，脾脏体积减小，且血清中炎性因子水平减低，通过调节肠道菌群，明显减轻了ConA诱导的AIH的肝损伤。说明肠道菌群可以影响免疫功能，这个过程主要是通过改变肝脏免疫细胞的比例以及炎性因子的数量完成的。目前尚缺乏通过中医药调节肠道菌群来治疗AIH的文献报道，或许是一种新的治疗方向。</p></sec><sec id="s5_2"><title>3.2. PBC</title><p>PBC以免疫相关的胆道上皮细胞损伤、胆汁淤积和进行性纤维化等为主要特征，诊断上主要靠肝脏血清学检查以及抗线粒体抗体(AMA)的检查 [<xref ref-type="bibr" rid="hanspub.36486-ref24">24</xref>]。熊去氧胆酸(UDCA)是传统中药熊胆的提取物，有清热解毒、息风止痉、清肝明目的功效，中医很早就将其应用于肝胆系疾病的治疗。1999年美国FDA将UDCA批准为治疗PBC的药物。其治疗作用可能和参与调节患者的菌群有关。近年来在(PBC)肠道菌群紊乱研究领域取得了突破性进展，揭示了PBC的一种微生物学特征。</p><p>我们知道胆汁酸主要是通过肠道细菌进行分解代谢的，肠道菌群能够影响胆汁酸池的大小、胆汁酸水平以及FXR信号通路的表达 [<xref ref-type="bibr" rid="hanspub.36486-ref25">25</xref>] [<xref ref-type="bibr" rid="hanspub.36486-ref26">26</xref>] [<xref ref-type="bibr" rid="hanspub.36486-ref27">27</xref>]。相关的动物实验发现无菌小鼠的胆汁酸水平与正常饲养小鼠相比，肝组织中胆汁酸水平表现出较明显的升高 [<xref ref-type="bibr" rid="hanspub.36486-ref28">28</xref>]。一项随机对照前瞻性临床研究 [<xref ref-type="bibr" rid="hanspub.36486-ref29">29</xref>]，采集PBC患者与健康对照组患者的大便进行16S rRNA测序，通过横向对比发现PBC患者肠道菌群多样性较健康对照组显著降低(p = 0.03)，给予PBC患者UDCA治疗6个月，PBC相关属的菌群丰度增加。以上研究表明肠道菌群在PBC的发生以及治疗中发挥重要作用，是否能作为PBC的治疗靶点和生物标志物有待于进一步研究证实。</p></sec><sec id="s5_3"><title>3.3. PSC</title><p>PSC是一种罕见的慢性胆汁淤积性肝脏疾病，以胆管的炎症和纤维化为特点，病情严重时可发展为胆管狭窄甚至肝硬化，多数患者合并有炎症性肠病。目前PSC的发病机制尚不清楚，大多认为是遗传和免疫相互作用的结果，通过临床表现、生化和组织学的检查以及胆道造影可诊断该病 [<xref ref-type="bibr" rid="hanspub.36486-ref30">30</xref>]。有一部分PSC患者可无临床症状，有症状的PSC患者通常以乏力、黄疸、瘙痒、腹部不适等症状为特征。缺乏有效治疗药物，目前的治疗主要依靠肝移植 [<xref ref-type="bibr" rid="hanspub.36486-ref31">31</xref>]。有人采用UDCA治疗PSC，但需要长期大剂量服用药物，副作用较大。可作为经验性用药，不推荐长期大剂量服用 [<xref ref-type="bibr" rid="hanspub.36486-ref30">30</xref>]。</p><p>Pereira等人 [<xref ref-type="bibr" rid="hanspub.36486-ref32">32</xref>] 提出PSC的病因与胆汁微生物群落的变化无关，认为链球菌在该病的发展过程中发挥了潜在的致病作用。Tabibian等 [<xref ref-type="bibr" rid="hanspub.36486-ref33">33</xref>] 的研究发现，将Mdr2-小鼠于无菌环境中饲养2个月以后，其ALP、转氨酶、胆红素等血清学指标，次级胆汁酸缺失，升高更明显，纤维化、胆管狭窄更严重，UDCA治疗以后以上症状均有所好转，提示肠道菌群及其代谢产物在预防胆道损伤中的重要性，并为今后研究PSC的生物标志物和治疗干预措施提供了途径。粪菌移植或可成为PSC潜在的治疗手段。</p></sec></sec><sec id="s6"><title>4. 粪菌移植治疗</title><p>粪菌移植是指将健康人的正常菌群经过处理以后，移植给患者的一种治疗方法。自从粪菌移植用于治疗难治性腹泻并能够使菌群恢复平衡 [<xref ref-type="bibr" rid="hanspub.36486-ref34">34</xref>]，粪菌移植的治疗手段在各种肠道菌群相关性疾病中广泛应用，也激起了广大学者的研究热情。</p><p>研究表明，来自健康供体的微生物群可以恢复肠道菌群紊乱患者肠道菌群的结构 [<xref ref-type="bibr" rid="hanspub.36486-ref35">35</xref>]。AILD也是一种菌群相关性疾病。Allegretti JR等 [<xref ref-type="bibr" rid="hanspub.36486-ref36">36</xref>] 对10例PSC患者进行FMT治疗，在基线和FMT后第1、4、8、12和24周进行肝酶谱、粪便微生物组和代谢组学分析，首次证明FMT在PSC治疗中的安全性，FMT术后第6个月ALP水平较基线下降 ≥ 50%；采用16S rRNA对粪便微生物和代谢动力学进行检测，菌群多样性较基线期增加，且与ALP水平下降相关(P = 0.02)。最近的一例病例报道 [<xref ref-type="bibr" rid="hanspub.36486-ref37">37</xref>]，评价FMT治疗原发性硬化性胆管炎复发性急性细菌性胆管炎的疗效，进行为期4周，每周1次的治疗，分别在基线、每次FMT前和治疗后1年结束时，对血液生化、总胆汁酸和分离血清胆汁酸和粪便微生物群落进行检测，结果显示虽然FMT治疗后，患者的变形杆菌相对丰度降低，拟杆菌和厚壁杆菌数量增加，血液生化、总胆汁酸和分离血清胆汁酸指标有所好转，但是随访一年后这些指标又逐渐变差。这些问题需要进一步使用综合多组学大规模的研究，来证实FMT应用于PSC的疗效，并且要长期随访评估疗效。</p></sec><sec id="s7"><title>5. 小结与展望</title><p>基于肠道菌群的治疗方法，确实在一些AILD患者的治疗中发挥了重要作用，但是其具体的机制尚未完全阐明，并且大样本的随机临床试验研究还不够完善，故研究作用机制以及设计更加规范合理的实验方案来证明长期疗效是我们未来努力的方向。随着医学的发展以及研究的逐步深入，利用先进的检测手段和科学的实验方法，将会为AILD的诊断和治疗找到一个更加绿色有效的道路，为全人类的健康事业保驾护航，促进构建人类命运共同体。</p></sec><sec id="s8"><title>基金项目</title><p>上海市体育局资助项目(编号：19Z010)；中医脾胃病专科。</p></sec><sec id="s9"><title>文章引用</title><p>石莉杰,李雪微,李艳英,沙 敏,诸慧怡,何 进,黄天生. 肠道菌群在自身免疫性肝病中的治疗进展Progress of Intestinal Flora in the Treatment of Autoimmune Liver Disease[J]. 中医学, 2020, 09(04): 348-353. https://doi.org/10.12677/TCM.2020.94052</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.36486-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Qin, J., Li, R., Raes, J., et al. (2010) A Human Gut Microbial Gene Catalogue Established by Metagenomic Sequencing. Nature, 464, 59-65. &lt;br&gt;https://doi.org/10.1038/nature08821</mixed-citation></ref><ref id="hanspub.36486-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Deschasaux, M., Bouter, K.E., Prodan, A., et al. (2018) Depicting the Composition of Gut Microbiota in a Population with Varied Ethnic Origins But Shared Geography. Nature Medicine, 24, 1526-1531. &lt;br&gt;https://doi.org/10.1038/s41591-018-0160-1</mixed-citation></ref><ref id="hanspub.36486-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, C., Zhang, M., Wang, S., et al. (2010) Interactions be-tween Gut Microbiota, Host Genetics and Diet Relevant to Development of Metabolic Syndromes in Mice. The ISME Journal, 4, 232-241. &lt;br&gt;https://doi.org/10.1038/ismej.2009.112</mixed-citation></ref><ref id="hanspub.36486-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Madan, J.C., Hoen, A.G., Lundgren, S.N., et al. (2016) Association of Cesarean Delivery and Formula Supplementation with the Intestinal Microbiome of 6-Week-Old Infants. JAMA Pe-diatrics, 170, 212-219. &lt;br&gt;https://doi.org/10.1001/jamapediatrics.2015.3732</mixed-citation></ref><ref id="hanspub.36486-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Paolella, G. (2014) Gut-Liver Axis and Probiotics: Their Role in Non-Alcoholic Fatty Liver Disease. World Journal of Gastroenterology, 20, 15518-15531. &lt;br&gt;https://doi.org/10.3748/wjg.v20.i42.15518</mixed-citation></ref><ref id="hanspub.36486-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Chang, C., Lin, C., Lu, C., et al. (2015) Ganodermalucidum Re-duces Obesity in Mice by Modulating the Composition of the Gut Microbiota. Nature Communications, 6, 7489. &lt;br&gt;https://doi.org/10.1038/ncomms8489</mixed-citation></ref><ref id="hanspub.36486-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Brahe, L.K., Astrup, A. and Larsen, L.H. (2016) Can We Prevent Obe-sity-Related Metabolic Diseases by Dietary Modulation of the Gut Microbiota? Advances in Nutrition, 7, 90-101. &lt;br&gt;https://doi.org/10.3945/an.115.010587</mixed-citation></ref><ref id="hanspub.36486-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Sonnenburg, J.L. and Bäckhed, F. (2016) Diet-Microbiota Interactions as Moderators of Human Metabolism. Nature, 535, 56-64. &lt;br&gt;https://doi.org/10.1038/nature18846</mixed-citation></ref><ref id="hanspub.36486-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Herrema, H., IJzerman, R.G. and Nieuwdorp, M. (2017) Emerging Role of Intestinal Microbiota and Microbial Metabolites in Metabolic Control. Diabetologia, 60, 613-617. &lt;br&gt;https://doi.org/10.1007/s00125-016-4192-0</mixed-citation></ref><ref id="hanspub.36486-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Cotillard, A., Kennedy, S.P., Kong, L.C., et al. (2013) Dietary Intervention Impact on Gut Microbial Gene Richness. Nature, 500, 585-588. &lt;br&gt;https://doi.org/10.1038/nature12480</mixed-citation></ref><ref id="hanspub.36486-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Kamada, N., Seo, S.U., Chen, G.Y., et al. (2013) Role of the Gut Microbiota in Immunity and Inflammatory Disease. Nature Reviews Immunology, 13, 321-335. &lt;br&gt;https://doi.org/10.1038/nri3430</mixed-citation></ref><ref id="hanspub.36486-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Bajaj, J.S., Hylemon, P.B. and Younossi, Z. (2012) The Intestinal Microbiota and Liver Disease. American Journal of Gastroenterology Supplements, 1, 9-14.</mixed-citation></ref><ref id="hanspub.36486-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Boursier, J., Mueller, O., Barret, M., et al. (2016) The Severity of Nonalcoholic Fatty Liver Disease Is Associated with Gut Dysbiosis and Shift in the Metabolic Function of the Gut Microbiota. Hepatology, 63, 764-775. &lt;br&gt;https://doi.org/10.1002/hep.28356</mixed-citation></ref><ref id="hanspub.36486-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Xie, G., Wang, X., Liu, P., et al. (2016) Distinctly Altered Gut Microbiota in the Progression of Liver Disease. Oncotarget, 7, 19355-19366. &lt;br&gt;https://doi.org/10.18632/oncotarget.8466</mixed-citation></ref><ref id="hanspub.36486-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Li, F., Sun, G., Wang, Z., et al. (2018) Characteristics of Fecal Microbiota in Non-Alcoholic Fatty Liver Disease Patients. Science China Life Sciences, 61, 770-778. &lt;br&gt;https://doi.org/10.1007/s11427-017-9303-9</mixed-citation></ref><ref id="hanspub.36486-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Yin, X., Peng, J., Zhao, L., et al. (2013) Structural Changes of Gut Microbiota in a Rat Non-Alcoholic Fatty Liver Disease Model Treated with a Chinese Herbal Formula. Systematic and Applied Microbiology, 36, 188-196. &lt;br&gt;https://doi.org/10.1016/j.syapm.2012.12.009</mixed-citation></ref><ref id="hanspub.36486-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Lynch, S.V. and Pedersen, O. (2016) The Human Intestinal Microbiome in Health and Disease. The New England Journal of Medicine, 375, 2369-2379. &lt;br&gt;https://doi.org/10.1056/NEJMra1600266</mixed-citation></ref><ref id="hanspub.36486-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Li, B., Selmi, C., Tang, R., et al. (2018) The Microbiome and Au-toimmunity: A Paradigm from the Gut-Liver Axis. Cellular &amp; Molecular Immunology, 15, 595-609. &lt;br&gt;https://doi.org/10.1038/cmi.2018.7</mixed-citation></ref><ref id="hanspub.36486-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Marshall, J.C. (1998) The Gut as a Potential Trigger of Exercise-Induced Inflammatory Responses. Canadian Journal of Physiology and Pharmacology, 76, 479-484. &lt;br&gt;https://doi.org/10.1139/y98-049</mixed-citation></ref><ref id="hanspub.36486-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">陈成伟, 陈晓宇, 成军. 自身免疫性肝炎诊断和治疗共识(2015)[J]. 国际消化病杂志, 2016, 21(1): 165-178.</mixed-citation></ref><ref id="hanspub.36486-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Peiseler, M., Liebscher, T., Sebode, M., et al. (2018) Efficacy and Limitations of Budesonide as a Second-Line Treatment for Patients with Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology, 16, 260-267. &lt;br&gt;https://doi.org/10.1016/j.cgh.2016.12.040</mixed-citation></ref><ref id="hanspub.36486-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">林睿. 肠黏膜屏障损伤对自身免疫性肝炎患者枯否细胞免疫调节功能影响的研究[D]: [博士学位论文]. 天津: 天津医科大学, 2013.</mixed-citation></ref><ref id="hanspub.36486-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">王禾穗源, 杨成茂, 郭倩, 等. 肠道菌群对于CONA诱导的自身免疫性肝炎的影响[C]//第八届泛环渤海生物化学与分子生物学会2018年学术交流会, 2018: 115.</mixed-citation></ref><ref id="hanspub.36486-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">李谦谦, 周新苗, 祁兴顺, 等. 《2018年英国胃肠病学会/英国PBC协作组原发性胆汁性胆管炎治疗及管理指南》推荐意见[J]. 临床肝胆病杂志, 2018, 34(6): 1191-1192.</mixed-citation></ref><ref id="hanspub.36486-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Fiorucci, S. and Distrutti, E. (2015) Bile Acid-Activated Receptors, Intestinal Microbiota, and the Treatment of Metabolic Disorders. Trends in Molecular Medicine, 21, 702-714. &lt;br&gt;https://doi.org/10.1016/j.molmed.2015.09.001</mixed-citation></ref><ref id="hanspub.36486-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Chiang, J.Y.L., Kimmel, R., Wein-berger, C., et al. (2000) Farnesoid X Receptor Responds to Bile Acids and Represses Cholesterol 7α-Hydroxylase Gene (CYP7A1) Transcription. Journal of Biological Chemistry, 275, 10918-10924. &lt;br&gt;https://doi.org/10.1074/jbc.275.15.10918</mixed-citation></ref><ref id="hanspub.36486-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Gadaleta, R.M., van Erpecum, K.J., Oldenburg, B., et al. (2011) Farnesoid X Receptor Activation Inhibits Inflammation and Preserves the Intestinal Barrier in Inflammatory Bowel Disease. Gut, 60, 463-472. &lt;br&gt;https://doi.org/10.1136/gut.2010.212159</mixed-citation></ref><ref id="hanspub.36486-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Swann, J.R., Want, E.J., Geier, F.M., et al. (2011) Systemic Gut Microbial Modulation of Bile Acid Metabolism in Host Tissue Compartments. Proceedings of the National Academy of Sciences, 108, 4523-4530. &lt;br&gt;https://doi.org/10.1073/pnas.1006734107</mixed-citation></ref><ref id="hanspub.36486-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Tang, R., Wei, Y., Li, Y., et al. (2018) Gut Microbial Profile Is Altered in Primary Biliary Cholangitis and Partially Restored after UDCA Therapy. Gut, 67, 534-541. &lt;br&gt;https://doi.org/10.1136/gutjnl-2016-313332</mixed-citation></ref><ref id="hanspub.36486-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 原发性硬化性胆管炎诊断和治疗专家共识(2015)[J]. 临床肝胆病杂志, 2016, 32(1): 23-31.</mixed-citation></ref><ref id="hanspub.36486-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Lazaridis, K.N. and LaRusso, N.F. (2016) Primary Sclerosing Cholangitis. The New England Journal of Medicine, 375, 1161-1170. &lt;br&gt;https://doi.org/10.1056/NEJMra1506330</mixed-citation></ref><ref id="hanspub.36486-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Pereira, P., Aho, V., Arola, J., et al. (2017) Bile Microbiota in Primary Sclerosing Cholangitis: Impact on Disease Progression and Development of Biliary Dysplasia. PLoS ONE, 12, e182924. &lt;br&gt;https://doi.org/10.1371/journal.pone.0182924</mixed-citation></ref><ref id="hanspub.36486-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Tabibian, J.H., Hara, S.P.O., Trussoni, C.E., et al. (2016) Ab-sence of the Intestinal Microbiota Exacerbates Hepatobiliary Disease in a Murine Model of Primary Sclerosing Chol-angitis. Hepatology, 63, 185-196. &lt;br&gt;https://doi.org/10.1002/hep.27927</mixed-citation></ref><ref id="hanspub.36486-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">de Vrieze, J. (2013) The Promise of Poop. Science, 341, 954-957. &lt;br&gt;https://doi.org/10.1126/science.341.6149.954</mixed-citation></ref><ref id="hanspub.36486-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Hamilton, M.J., Weingarden, A.R., Unno, T., et al. (2013) High-Throughput DNA Sequence Analysis Reveals Stable Engraftment of Gut Microbiota Following Transplantation of Previously Frozen Fecal Bacteria. Gut Microbes, 4, 125-135. &lt;br&gt;https://doi.org/10.4161/gmic.23571</mixed-citation></ref><ref id="hanspub.36486-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Allegretti, J.R., Kassam, Z., Carrellas, M., et al. (2019) Fecal Microbiota Transplantation in Patients with Primary Sclerosing Cholangitis. The American Journal of Gastroenterology, 114, 1071-1079. &lt;br&gt;https://doi.org/10.14309/ajg.0000000000000317</mixed-citation></ref><ref id="hanspub.36486-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Philips, C.A., Augustine, P. and Phadke, N. (2018) Healthy Donor Fecal Microbiota Transplantation for Recurrent Bacterial Cholangitis in Primary Sclerosing Cholangitis—A Single Case Report. Journal of Clinical and Translational Hepatology, 6, 438-441. &lt;br&gt;https://doi.org/10.14218/JCTH.2018.00033</mixed-citation></ref></ref-list></back></article>